Why Specialized Research Platforms Matter in Modern Drug Development

The pharmaceutical landscape is undergoing a paradigm shift. Traditional small-molecule drugs are increasingly complemented — and in some therapeutic areas, replaced — by novel modalities such as mRNA vaccines, CAR-T cell therapies, antibody-drug conjugates (ADCs), nucleic acid therapeutics, and advanced drug delivery systems. These innovative approaches demand evaluation platforms that go far beyond conventional cell-based assays and standard animal models.

Specialized research platforms are purpose-designed to address the unique challenges posed by next-generation therapeutics:

• Complex mechanisms of action — immunotherapies and gene therapies require multi-step functional evaluation that standard efficacy assays cannot capture
• Route-specific delivery challenges — inhaled therapeutics, nucleic acid delivery vectors, and targeted molecular carriers require dedicated pharmacokinetic and biodistribution assessments
• Disease-specific microenvironments — liver diseases, lung pathologies, and tumor immune niches necessitate organ-specific and tissue-contextual evaluation systems
• Regulatory complexity — novel modalities face evolving regulatory frameworks that demand comprehensive mechanistic data, immunogenicity profiling, and off-target safety assessments

At Jennio Biotech, we have invested in five specialized platforms to address these exact needs. Each platform combines dedicated equipment, validated assay systems, and domain-specific scientific expertise to deliver the deep, mechanism-rich data that sponsors need to advance innovative therapeutics through preclinical development and into clinical trials.

Five Specialized Platforms for Innovative Drug Development

Each of our specialized platforms addresses a distinct therapeutic modality or delivery technology, supported by dedicated scientific teams and purpose-built infrastructure.

Explore Our Specialized Research Platforms

Click on each platform below to learn more about our specialized capabilities.

Tumor Vaccine Development Platform

Cancer vaccines represent one of the most promising frontiers in immuno-oncology, harnessing the patient’s own immune system to recognize and eliminate tumor cells. Jennio Biotech’s tumor vaccine development platform provides end-to-end preclinical evaluation services for cancer vaccine candidates — from antigen design validation to in vivo immunogenicity and anti-tumor efficacy assessment.

• Antigen Design & Validation — in silico neoantigen prediction support, peptide/MHC binding assays (ELISpot, tetramer staining), and dendritic cell activation studies to confirm antigen immunogenicity before in vivo testing
• Humanized Target Gene Tumor Models — genetically engineered mouse models expressing human tumor-associated antigens or HLA alleles for evaluating HLA-restricted T cell responses and vaccine-elicited anti-tumor immunity in a physiologically relevant context
• Immunogenicity Profiling — comprehensive immune monitoring including antigen-specific T cell responses (IFN-γ ELISpot, intracellular cytokine staining), antibody titer measurement (ELISA), and memory T cell characterization (central vs. effector phenotypes)
• Anti-Tumor Efficacy — prophylactic and therapeutic vaccination studies in syngeneic, humanized, and xenograft tumor models with tumor growth monitoring, survival analysis, and immune cell infiltration assessment (IHC, flow cytometry)
• Combination Strategy Evaluation — testing vaccine candidates in combination with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4), adjuvants, chemotherapy, or radiation to identify synergistic regimens

Our platform supports mRNA vaccines, peptide vaccines, DNA vaccines, dendritic cell vaccines, and oncolytic virus-based vaccine candidates. We provide detailed immunological data packages suitable for IND-enabling submissions. Explore Tumor Vaccine Platform →

Cell Therapy Evaluation Platform

Cell-based therapies — including CAR-T, CAR-NK, TCR-T, and mesenchymal stem cell (MSC) products — represent transformative treatment modalities for cancer, autoimmune diseases, and regenerative medicine. However, evaluating these living therapeutics requires specialized platforms that can assess both efficacy and safety in immunologically relevant contexts.

• In Vitro Cell Potency & Cytotoxicity Assays — standardized cytotoxicity assays (lactate dehydrogenase release, real-time cell killing analysis, flow cytometry-based killing assays) against target tumor cell panels at multiple effector-to-target (E:T) ratios to determine cell therapy potency and antigen-specific killing
• Cell Phenotype & Quality Control — comprehensive characterization of therapeutic cell products including surface marker profiling (CD3, CD4, CD8, CAR expression, NK markers), differentiation/exhaustion status (PD-1, TIM-3, LAG-3, TIGIT), and cytokine production profiles (IFN-γ, TNF-α, IL-2)
• In Vivo Efficacy Studies — evaluation of cell therapy products in xenograft, PDX, and humanized immune system (HIS) mouse models with tumor burden monitoring, bioluminescence imaging, and overall survival assessment
• Cytokine Release Syndrome (CRS) Modeling — in vivo models to evaluate cytokine release kinetics (IL-6, IL-1β, IFN-γ, TNF-α) and potential toxicity of cell therapy products, supporting safety profiling and dose optimization
• Persistence & Biodistribution — tracking of administered therapeutic cells using flow cytometry, qPCR, or bioluminescence imaging to assess in vivo expansion, persistence, and tissue distribution over time

Explore Cell Therapy Platform →

Inhalation Therapy Drug Evaluation Platform

Pulmonary drug delivery offers distinct therapeutic advantages for respiratory diseases (asthma, COPD, pulmonary fibrosis, lung infections) and systemic conditions requiring non-invasive administration. However, inhaled drug products present unique development challenges related to aerosol physics, lung deposition, local pharmacokinetics, and pulmonary safety. Jennio Biotech’s inhalation therapy platform addresses these challenges with dedicated equipment and specialized expertise.

• Aerosol & Formulation Characterization — particle size distribution analysis (laser diffraction, cascade impaction), aerodynamic diameter measurement (MMAD, GSD), and spray pattern/plume geometry assessment for nebulizers, MDIs, and DPIs
• In Vivo Pulmonary Delivery Studies — oropharyngeal or intratracheal administration of inhaled drug formulations in rodent models, with standardized dosing protocols that mimic clinical inhalation exposure patterns
• Lung Deposition & Biodistribution — quantitative assessment of drug deposition in lung tissue and distribution to systemic organs using LC-MS/MS or radiolabeling techniques, supporting pulmonary PK/PD characterization
• Pulmonary Efficacy Models — evaluation of inhaled therapeutics in disease-relevant models including bleomycin-induced pulmonary fibrosis, LPS-induced acute lung injury, OVA-induced asthma, and cigarette smoke-induced COPD models
• Pulmonary Safety Assessment — bronchoalveolar lavage fluid (BALF) analysis (total cell count, differential, cytokines), lung histopathology, and pulmonary function testing (plethysmography) to evaluate local tolerability and potential pulmonary toxicity

Explore Inhalation Therapy Platform →

Liver Disease Research Platform

Liver diseases — including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis, liver fibrosis, and cholestatic liver diseases — represent a massive and growing global health burden with very limited approved therapeutic options. The complex pathophysiology of liver diseases, involving lipid metabolism dysregulation, inflammation, fibrogenesis, and cholestasis, demands specialized evaluation platforms.

• NAFLD/NASH Models — multiple validated preclinical models including methionine-choline deficient (MCD) diet, high-fat diet (HFD) + fructose/glucose, STAM (streptozotocin + HFD), and Western diet + CCl4 models, each recapitulating different aspects of human NASH pathology (steatosis, inflammation, ballooning, fibrosis)
• Comprehensive Liver Histopathology — expert pathological evaluation using NAFLD Activity Score (NAS), steatosis/lobular inflammation/ballooning scoring, and fibrosis staging (Kleiner, NASH CRN), with Masson’s trichrome, Sirius Red, and Oil Red O staining
• Hepatic Fibrosis Assessment — quantitative hydroxyproline content measurement, liver stiffness assessment, α-SMA IHC, and fibrosis-related gene expression profiling (COL1A1, COL3A1, TGF-β, TIMP-1) for evaluating anti-fibrotic drug candidates
• Biochemical & Metabolic Endpoints — serum ALT/AST, liver function panel (ALP, GGT, total bilirubin, albumin), hepatic lipid profiling (triglycerides, cholesterol), and bile acid analysis for comprehensive liver function characterization
• Viral Hepatitis Models — HBV and HCV infection models (including our established HBV transgenic platform) for evaluating antiviral therapeutics, host-targeting agents, and immunotherapeutic approaches against chronic viral hepatitis

Explore Liver Disease Platform →

Molecular Delivery Efficiency Research Platform

The therapeutic potential of many drug candidates — including nucleic acid therapeutics, antibody-drug conjugates (ADCs), targeted nanoparticles, and bispecific antibodies — is fundamentally dependent on efficient and specific molecular delivery to the intended target tissue, cell type, or subcellular compartment. Jennio Biotech’s molecular delivery efficiency platform provides the specialized analytical capabilities needed to quantify, optimize, and validate delivery performance.

• Biodistribution & Tissue Targeting Analysis — quantitative measurement of drug concentration across major organs (liver, lung, spleen, kidney, heart, brain, tumor) and plasma using LC-MS/MS, ELISA, or fluorescence-based methods to determine tissue-to-plasma ratios, target-to-off-target accumulation ratios, and overall biodistribution profiles
• Intracellular Delivery Efficiency — assessment of cellular uptake, endosomal escape, and subcellular localization of delivered molecules using confocal microscopy, flow cytometry, and fractionation techniques, particularly relevant for LNP-formulated nucleic acid therapeutics and cell-penetrating peptides
• ADC Target Engagement & Payload Delivery — evaluation of ADC binding specificity, internalization kinetics, payload release efficiency, and bystander killing effect using in vitro and in vivo models, supporting ADC optimization programs
• Off-Target & Immunogenicity Assessment — screening for unintended tissue accumulation, anti-drug antibody (ADA) formation, and complement activation to support delivery system safety profiling
• LNP & Nanoparticle Characterization — particle size (DLS), zeta potential, encapsulation efficiency, drug loading capacity, and in vitro release kinetics for lipid nanoparticles, polymeric nanoparticles, and other nanocarrier systems

Explore Molecular Delivery Platform →

Why Choose Jennio Biotech’s Specialized Platforms

1. Purpose-Built Infrastructure for Novel Modalities

Standard CRO facilities are designed for conventional drug evaluation. Our specialized platforms are equipped with dedicated instrumentation — aerosol characterization systems, biosafety containment for viral vectors, flow cytometry panels optimized for cell therapy analysis, and advanced imaging capabilities — that standard preclinical labs lack.

2. Deep Scientific Expertise in Cutting-Edge Therapeutics

Our platform scientists are not generalists — they are domain specialists with hands-on experience in vaccine immunology, cell therapy biology, pulmonary delivery science, hepatology, and drug delivery technology. This specialization translates directly into better experimental design, more insightful data interpretation, and more reliable preclinical predictions.

3. Seamless Integration with Standard Efficacy Platforms

Each specialized platform integrates with Jennio Biotech’s broader in vitro and in vivo efficacy research services. A cell therapy program, for example, can leverage our cell bank for target cell selection, our functional assay platform for potency testing, and our in vivo pharmacology team for animal studies — all within a single coordinated program.

4. Regulatory-Ready Data Packages

We understand the evolving regulatory expectations for novel modalities and design our studies to generate data packages that support IND submissions. From comprehensive immunogenicity profiling for cell therapies to biodistribution studies for gene therapy delivery vectors, we produce the data that regulators expect to see.

Frequently Asked Questions

What types of tumor vaccines can you evaluate on your platform?
Our tumor vaccine development platform supports evaluation of all major cancer vaccine modalities including mRNA-based vaccines, peptide vaccines, DNA vaccines, dendritic cell (DC) vaccines, viral vector-based vaccines, and oncolytic virus platforms. We design customized immunogenicity testing strategies based on the vaccine type, target antigens, and intended clinical application (prophylactic vs. therapeutic).

Do you provide cell therapy manufacturing support, or only efficacy evaluation?
Our platform focuses on preclinical efficacy evaluation and characterization of cell therapy products. This includes in vitro potency/cytotoxicity assays, cell product phenotyping and QC characterization, in vivo efficacy studies, CRS modeling, and biodistribution assessment. We do not currently offer GMP manufacturing services, but we can evaluate cells produced by your manufacturing process and provide analytical support to bridge manufacturing and clinical development.

What inhaled formulation types does your inhalation platform support?
Our inhalation therapy evaluation platform supports all major inhaled dosage forms including nebulizer solutions/suspensions, metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers. We can characterize aerosol properties, conduct in vivo pulmonary delivery studies, and evaluate therapeutic efficacy and pulmonary safety across all these formulation types.

Can you test LNP-formulated mRNA therapeutics on your molecular delivery platform?
Yes. Our molecular delivery efficiency platform is specifically designed to support evaluation of LNP-formulated therapeutics including mRNA vaccines, siRNA, and other nucleic acid-based drug candidates. We provide comprehensive characterization including particle size and zeta potential measurement, encapsulation efficiency, in vitro cellular uptake and endosomal escape assessment, in vivo biodistribution across major organs, and intracellular delivery efficiency quantification.

Which NASH model do you recommend for anti-fibrotic drug evaluation?
The optimal NASH model depends on your drug’s mechanism of action and development stage. For anti-fibrotic candidates, the STAM model (streptozotocin + high-fat diet) and Western diet + CCl4 model are preferred because they develop robust fibrosis within 8–12 weeks. For anti-steatotic or anti-inflammatory candidates, the MCD model and HFD + fructose models provide strong readouts for lipid accumulation and inflammation, respectively. Our scientific team will recommend the most appropriate model based on your specific program during project consultation.

Advancing innovative therapeutics requires specialized expertise. Contact our specialized platform team to discuss your novel modality evaluation needs. We’ll respond within 24 hours with a tailored project proposal.
Email: 3691125803@qq.com | Phone/WeChat: +86 18802035152